Examkin

Question

Difficulty: EasyBipolar and Related Disorders

An established patient presents to the outpatient psychiatry clinic accompanied by her sister. The 29-year-old woman reports feeling profoundly 'empty' and exhausted for the past three weeks. During this time, she has struggled with significant hypersomnia, hyperphagia, and pervasive feelings of guilt. Her sister notes that two years prior, the patient experienced a highly uncharacteristic 10-day period during which she was exceptionally 'wired,' slept merely two hours per night, spoke incessantly, and had grandiose delusions of being a secret government agent. She was subsequently placed on phenelzine for presumed unipolar depression by a different provider, but she independently stopped taking this medication 3 days ago due to a lack of perceived efficacy. Current laboratory results, including a complete thyroid panel (TSH and free T4), are within normal limits. Which of the following is the most appropriate next step in the pharmacologic management of this patient?

  1. Initiate lithiumAnswer
  2. B
    Delay pharmacotherapy for 14 days, then initiate sertraline
  3. C
    Initiate sertraline immediately
  4. D
    Initiate levothyroxine
  5. E
    Initiate risperidone

Answer

Initiate lithium
The correct answer is to initiate lithium. This patient presents with a current depressive episode (marked by low mood, hypersomnia, hyperphagia, and excessive guilt) and a documented history of a distinct 10-day episode characterized by a decreased need for sleep, rapid speech, and grandiose delusions. This history firmly meets the criteria for a manic episode, establishing the diagnosis of bipolar I disorder. Therefore, the patient is currently experiencing bipolar depression. First-line pharmacologic treatments for bipolar depression include lithium, lurasidone, or quetiapine. Because the patient recently discontinued phenelzine (an MAOI) just 3 days ago, extreme care must be taken to avoid dangerous drug interactions. However, lithium does not act as a serotonergic reuptake inhibitor, does not cause serotonin syndrome, and can therefore be safely initiated without waiting for a 14-day washout period.

Step-by-Step Solution

1
Diagnose the primary psychiatric condition based on the patient's history.
The patient has a history of a 10-day manic episode (decreased sleep, rapid speech, impulsivity, grandiose delusions) and is currently presenting with depression, which confirms a diagnosis of Bipolar I Disorder.
Accurate diagnosis is strictly required to select the appropriate pharmacotherapy and avoid contraindicated medications, such as antidepressant monotherapy.
2
Evaluate the current medication history for potential drug interactions.
The patient discontinued phenelzine (an MAOI) 3 days ago. A 14-day washout period is mandatory before starting any serotonergic agents to prevent serotonin syndrome.
Irreversible MAOIs continue to inhibit the monoamine oxidase enzyme for up to two weeks after they are discontinued.
3
Select a safe and effective first-line medication for bipolar depression.
Lithium is selected because it is a proven first-line treatment for bipolar depression and does not interact with MAOIs to cause serotonin syndrome.
Lithium stabilizes mood without the risk of precipitating mania, unlike SSRIs, and can be started immediately without a washout period.

Key Concept

Patients with bipolar I depression require mood-stabilizing medications (such as lithium) rather than antidepressant monotherapy to avoid precipitating mania. Furthermore, a strict 14-day washout is critical when transitioning from an MAOI to any serotonergic drug, but not for lithium.
Rate this question

Topics

Bipolar and Related Disorders

More questions from this topic